Canadian Women’s Network Pathway to Silicon Valley Week
perrin2023-04-18T20:06:51+00:00Date: April 17-20
Venue: Silicon Valley
Date: April 17-20
Venue: Silicon Valley
Canadian Women's Network Pathway to Silicon Valley Week
Our COO Catalina Vasquez is attending the Canadian Women’s Network pathway for Silicon Valley, now! For the next 4 days, she’s networking, learning, and building industry connections with investors, plus fellow executives and founders in Silicon Valley. For more info about this program click on the title above.
Date: March 10-13
Venue: In-person, Allianz MiCo, Milano Convention Centre, Milan, Italy
SESSION 04
ABSTRACT 0061
4th Annual AIMSSxGairdner AI Healthcare Conference
Date: March 10-12
Venue: In-person, and virtual, The Matrix Hotel, Edmonton, Alberta
68th Prairie Urological Association Annual Meeting – PUA 2023
Date: March 03-05
Venue: In-person, Lake Louise, Alberta
We developed the extracellular vesicle machine learning analysis platform (EVMAP) to improve the prediction of diseases such as cancer. The platform combines extracellular vesicle analysis using microscale cytometry with a machine learning approach to generate predictive models. In this work, we utilized EVMAP to generate a blood test to predict high-grade prostate cancer in men that was significantly more accurate than the prostate-specific antigen test. This platform could be applied to many different diseases.
JPM Week 2023
Date: January 9 to 12
Venue: In-person, San Francisco, CA
Edmonton, Alberta – Nanostics Inc., a precision health diagnostics company, announced today the appointment of Aubrey Rankin to its Board of Directors. Mr. Rankin will join the board of directors at Nanostics replacing Mr. Reg Joseph as one of the independent directors for the company.
“We’re excited to announce Aubrey Rankin’s appointment to Nanostics’ Board of Directors. Aubrey’s vast experience and insights with patient-provider subscription platforms will be invaluable as we launch our lead prostate cancer diagnostic test, ClarityDX Prostate®,” said John Lewis, CEO of Nanostics.
Nanostics sends thanks to outgoing board member Reg Joseph, CEO of Health City, for his service. Reg’s insights into the Healthcare Industry were instrumental in helping Nanostics advance its lead diagnostic product, ClarityDX Prostate® through clinical studies and position it for regulatory approval.
ISEVxTech Conference
Date: November 16 to 18
Venue: In-person, Waikiki Beach Marriot Resort, Honolulu, HI
CanPath Webinar with Dr. John Lewis
WEBINAR TO BE RESCHEDULED
Webinar: Predicting diseases through machine learning models
Date: Tuesday, November 22. 2022. New date TBD – please check back for updates.
Venue: Online – for more details and to register go to Event Link
Can Machine Learning models predict disease? Dr. John Lewis, Bird Dogs Chair in Translational Oncology at the University of Alberta, and CEO of Nanostics will talk about creating disease prediction models using CanPath questionnaire data, to help us understand the global risk factors of diseases like prostate cancer and how these risk factors differ for different populations.
Two powerhouse researchers in prostate cancer will change the way we treat the disease, thanks to funding from legendary volunteer fundraisers, the Bird Dogs and the Alberta Cancer Foundation.
Working with the Alberta Cancer Foundation and the University of Alberta, the Bird Dogs have enabled a new one-term, five-year chair position to further prostate cancer research — the Bird Dogs Chair in Translational Oncology, a position to be held by researcher Dr. John Lewis. For the last 10 years, Dr. Lewis has held the Frank and Carla Sojonky Chair in Prostate Cancer Research, made possible by a $5 million endowment from the Bird Dogs. Taking over from Dr. Lewis in this position will be surgeon-scientist, Dr. Adam Kinnaird.
© Copyright 2023 Nanostics | Designed by Forward Momentum | Powered by WordPress